Use of aryl-substituted polycyclic amines as medicaments

1. A method for the treatment of obesity which comprises administering to a patient in need of said treatment an effective amount of a compound of formula I:

wherein

A, B, D, and G are, independently of one another, N or C(R3);

R3 is H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R4)(R5), SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R6)(R7), N(R8)CO(R9), N(R10)SO 2 (R11), CO(R12), or (CR13R14) x —O(R15);

R4, R5, R6, R7, R8, R10 are, independently of one another, H or (C 1 -C 8 )-alkyl;

or, alternatively,

R4 and R5, R6 and R7

form, independently of one another, optionally together with the nitrogen atom to which they are bonded, a 5-6 membered ring which, apart from the nitrogen atom, may also include 1 further heteroatom-containing element selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

R9, R11, and R12 are, independently of one another, H, (C 1 -C 8 )-alkyl or aryl;

R13 and R14 are, independently of one another, H or (C 1 -C 8 )-alkyl;

R15 is H, (C 1 -C 6 )-alkyl or aryl;

x is 0, 1, 2, 3, 4, 5 or 6;

R1 is H, (C 1 -C 8 )-alkyl, (C 3 -C 6 )-alkenyl, or (C 3 -C 6 )-alkynyl;

X is N(R16), 0, a bond, (R17)C═C(R18), C≡C, or a group of the formula (CR19R20) y , in which one or two (CR19R20) groups may be replaced by Y;

Y is O, S, N(R21), or C═O;

R16, R17, and R18 are, independently of one another, H or (C 1 -C 8 )-alkyl;

R19 and R20 are, independently of one another, H or (C 1 -C 4 )-alkyl;

y is 1, 2, 3, 4, 5 or 6;

R21 is H or (C 1 -C 8 )-alkyl;

E is a 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms selected from the group consisting of N, O and S, which ring structure may optionally have substituents selected from the group consisting of H, F, Cl, Br, I, OH, CF 3 , CN, OCF 3 , oxo, O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 -alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, O—(C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R22)(R23), SO 2 —CH 3 , CON(R24)(R25), N(R26)CO(R27), N(R28)SO 2 (R29), and CO(R30) and may be mono- or bicyclic, wherein E is not a tetrazol-5-yl group;

R22, R23, R24, R25, R26, and R28 are, independently of one another, H, (C 1 -C 8 )-alkyl or aryl;

or, alternatively,

R22 and R23, R24 and R25 form, independently of one another, optionally together with the nitrogen atom to which they are bonded, a 5-6 membered ring which, apart from the nitrogen atom, may also include 1 further heteroatom-containing radical selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

R27, R29 and R30 are, independently of one another, H, (C 1 -C 8 )-alkyl or aryl;

K is a bond, C≡C, (R31)C═C(R32), or a group of the formula (CR33R34) z in which one or more (CR33R34) groups may be replaced by Z;

R31, R32, R35, R36, R37, R38, and R39 are, independently of one another, H or (C 1 -C 8 )-alkyl;

Z is O, S, N(R40), CO, SO, or SO 2 ;

R33 and R34 are, independently of one another, H, (C 1 -C 8 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, hydroxy, or (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl;

z is 1, 2, 3, 4, 5or 6;

R40 is H or (C 1 -C 8 )-alkyl;

R2 is H, (C 1 -C 8 )-alkyl, (C 1 -C 8 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 )-alkenyl, (C 3 -C 8 )-alkynyl, or a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, wherein the ring system may additionally be substituted with one or more of the following substituents: F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 0 -C 8 )-alkylene-aryl, oxo, CO(R41), CON(R42)(R43), hydroxy, COO(R44), N(R45)CO(C 1 -C 6 )-alkyl, N(R46)(R47), SO 2 CH 3 , SCF 3 and S—(C 1 -C 6 )-alkyl, and wherein R2 is not a tetrazol-5-yl group;

R41, R42, R43, R44, R45, R46, and R47 are, independently of one another, H or (C 1 -C 8 )-alkyl;

or, alternatively,

R42 and R43, R46 and R47 form, independently of one another, optionally together with the nitrogen atom to which they are bonded, a 5-6 membered ring which, apart from the nitrogen atom, may also include 1 further heteroatom-containing radical selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

E, K and R2 together form a tricyclic system wherein the rings may be, independently of one another, saturated, partially saturated or unsaturated and, in each case, comprise 3-8 ring atoms;

L is a (CR48R49) m , group in which one or more (CR48R49) groups may be replaced by M;

M is 0;

m is 1, 2, 3, 4, 5, or 6,

R48, and R49, are, independently of one another, H, (C 1 -C 6 )-alkyl, or aryl; and

Q is selected from the following structures:

or an N-oxide thereof or a physiologically tolerated salt thereof.

2. A method for the treatment of obesity which comprises administering to a patient in need of said treatment an effective amount of a compound of formula I:

wherein:

A, B, D, and G are, independently of one another, N, or C(R3);

R3 is H, F, Cl, Br, CF 3 , CN, O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, N(R4)(R5), SO 2 —CF 13 , CON(R6)(R7), N(R8)CO(R9), CO(R12), or (CR13R14) x —O(R15);

R4, R5, R6, R7, and R8 are, independently of one another, H or (C 1 -C 8 )-alkyl;

or, alternatively,

R4 and R5, R6 and R7 form, independently of one another, optionally together with the nitrogen atom to which they are bonded, a 5-6 membered ring which, apart from the nitrogen atom, may also include 1 further heteroatom-containing radical selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

R9 and R12 are, independently of one another, H or (C 1 -C 8 )-alkyl;

R13 and R14 are each H;

R15 is H or (C 1 -C 6 )-alkyl;

x is 0, 1 or 2;

R1 is H or (C 1 -C 8 )-alkyl;

X is N(R16), a bond, (R17)C═C(R18), C≡C, CH 2 —CH 2 , YCH 2 , or CH 2 Y;

Y is O, S or N(R21);

R16, R17 and R18 are, independently of one another, H or (C 1 -C 8 )-alkyl;

R21 is H or (C 1 -C 8 )-alkyl;

E is a 3-8 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms selected from the group consisting of N, O and S, which ring may optionally have substituents selected from the group consisting of H, F, Cl, Br, OH, CF 3 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R22)(R23), SO 2 —CH 3 , N(R26)CO(R27), N(R28)SO 2 (R29), and CO(R30) and may be mono- or bicyclic, provided that E is not a tetrazol-5-yl group;

R22 and R23 are, independently of one another, H or (C 1 -C 8 )-alkyl;

or, alternatively,

R22 and R23 form, optionally together with the nitrogen atom to which they are bonded, a 5-6 membered ring which, apart from the nitrogen atom, may also include 1 further heteroatom-containing radical selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

R27, R29 and R30 are, independently of one another, H or (C 1 -C 8 )-alkyl;

K is a bond, 0, OCH 2 , CH 2 O, S, SO, SO 2 , N(R35), N(R36)CO, N—SO 2 , CON(R37), (C(R38)(R39)) v CO, (R31)C═C(R32), CEC, SCH 2 , SO 2 CH 2 ;

v is 1, 2 or 3;

R31, R32, R35, R36, R37, R38 and R39 are, independently of one another, H or (C 1 -C 8 -alkyl;

R2 is (C 1 -C 8 -alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, or a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may include 0 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, wherein the ring system may additionally be substituted with one or more of the following substituents: F, Cl, Br, CF 3 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 0 -C 2 )-alkylene-aryl, oxo, CO(R41), CON(R42)(R43), hydroxy, N(R45)CO(C 1 -C 6 )-alkyl, N(R46)(R47) or SO 2 CH 3 ; preferably (C 1 -C 8 -alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, a 3 to 10-membered mono- or bicyclic ring which may include 0 to 2 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted with F, Cl, Br, CF 3 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, oxo, CO(R41), CON(R42)(R43), N(R45)CO(C 1 -C 6 )-alkyl and SO 2 CH 3 ;

R41, R42, R43, R45, R46 and R47 are, independently of one another, H or (C 1 -C 8 )-alkyl;

or

R42 and R43, R46 and R47 form, independently of one another, optionally together with the nitrogen atom to which they are bonded, a 5-6 membered ring which, apart from the nitrogen atom, may also include 1 further heteroatom-containing radical selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

L is a (C(R48)(R49)) 6 , group in which one member may be replaced by O;

m is 1, 2, 3 or 4;

R48 and R49 are each H; and

Q is selected from:

or an N-oxide thereof or a physiologically tolerated salt thereof.

3. The method as claimed in claim 2 , wherein Q is:

4. The method as claimed in claim 2 , in which the group L-Q has the following meanings:

5. The method as claimed in claim 1 , wherein:

A, B, D, and G are, independently of one another, N or C(R3), and the total number of nitrogen atoms in this ring is 0-2.

6. The method as claimed in claim 2 , wherein:

K is O, OCH 2 , CH 2 O, S, SO, SO 2 , N(R35), N(R36)CO, CON(R37), (C(R38)(R39)) v , CO, (R31)C═C(R32), C≡C, SCH 2 , or SO 2 .

7. The method as claimed in claim 1 , wherein:

A, B, D, and G are, independently of each other, C(R3);:

R3 is H, F, Cl, Br, CF 3 , CN, O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, N(R4)(R5), SO 2 —CH 3 , CON(R6)(R7), N(R8)CO(R9), CO(R12), or (CR13R14) x —O(R15);

R4, R5, R6, R7, and R8 are, independently of one another, H or (C 1 -C 8 )-alkyl;

or, alternatively,

R4 and R5, R6 and R7 form, independently of one another, optionally together with the nitrogen atom to which they are bonded, a 5-6 membered ring which, apart from the nitrogen atom, may also include 1 further heteroatom selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

R9 and R12 are, independently of one another, H or (C 1 -C 8 )-alkyl;

R13 and R14 are each H;

R15 is H or (C 1 -C 6 )-alkyl; and

x is 0, 1 or 2.

8. The method as claimed in claim 1 , wherein X is a bond or N(R16), in which R16 is H or (C 1 -C 8 )-alkyl.

9. The method as claimed in claim 2 , wherein K is OCH 2 , CH 2 O, N(R36)CO, CON(R37), (C(R38)(R39)) 2 , (R31)C═C(R32), C≡C, SCH 2 , or SO 2 CH 2 .

10. The method as claimed in claim 2 , wherein K is OCH 2 , CH 2 O, CON(R37), C≡C, or SCH 2 .